Exploratory factor and network analysis of 43 inflammatory plasma biomarkers and cognitive performance in Black adults

Product:
Inflammation Panel 250
Topic:
Inflammation
Disease Area:
Cognitive Decline
Sample Type:
Plasma

Abstract

Background
Systemic inflammation has been implicated in cognitive aging and neurodegeneration; however, inflammatory biomarkers are expressed in coordinated patterns rather than as isolated markers.

Objective
To identify latent inflammatory biomarker groupings and evaluate their associations with cognitive performance among midlife and older adults.

Methods
This cross-sectional study included 334 participants from the Aging Research Characterizing Health Exposome via Social Drivers (ARCHES) study. Cognitive performance was assessed using the Preclinical Alzheimer Cognitive Composite (PACC). Plasma inflammatory biomarkers were quantified using the NuLISA™ multiplex immunoassay platform. Exploratory factor analysis (EFA) (minimum residual extraction, oblimin rotation) identified latent inflammatory factors, retaining biomarkers with loadings ≥0.40. Factor scores were evaluated in multivariable linear regression models adjusted for age, sex, education, and genotype status; sensitivity analyses adjusted for socioeconomic context, medication use, BMI, lifestyle factors, and clinical diagnoses. Age-stratified and nonlinear spline analyses were conducted.

Results
27 of 43 biomarkers formed an eight-factor structure explaining 43% of variance. Two factors were significantly associated with cognitive performance after FDR correction. Factor 4 (CCL4, CXCL1, S100A12) and Factor 5 (IL2, IL5, IL13, IL10, CSF2) were inversely associated with PACC scores. These associations remained consistent across sensitivity analyses. Age-stratified analyses showed that several inflammatory factors were associated with cognitive performance among participants aged 45–<65 years, whereas no factors remained significant among participants aged ≥65 years after FDR correction. Nonlinear modeling indicated a non-linear age-cognitive performance relationship.

Conclusions
EFA identified clusters of correlated inflammatory biomarkers associated with cognitive performance in this cohort of midlife and older adults.

READ THE PUBLICATION

Authors and Affiliations

Ramkrishna K. Singh¹, Semere Bekena¹, Alexis I.B. Walker¹, Kaylin Taylor¹, Yiqi Zhu¹, Subrata Pal¹, Essa A. Mohamed², Jean-Francois Trani³,⁴,⁵, Ian Kaplan⁶, and Ganesh M. Babulal¹,²,⁶

¹ Department of Neurology, Washington University School of Medicine, St. Louis, MO, USA

² Departments of Neurology and Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA

³ School of Public Health, Washington University in St. Louis, St. Louis, MO, USA

⁴ Interdisciplinary Laboratory of Economic Sociology, National Conservatory of Arts and Crafts, Paris, France

⁵ Department of Psychology, University of Johannesburg, Johannesburg, South Africa

⁶ Norwegian Afghanistan Committee, Kabul, Afghanistan

Steve Williams, MD, PhD

CSO

Dr. Willams serves as the company’s Chief Scientific Officer. He was previously Chief Medical Officer at Standard Biotools and at SomaLogic where he pioneered the discipline for discovery and validation of predictive, diagnostic and prognostic models using machine-learning applied to large-plex proteomics. 20 such tests were used for drug characterization, safety and efficacy when incorporated in clinical drug trials at Pharma/Biotech and 17 different multivariate tests were validated and translated into regulated healthcare uses. Prior to SomaLogic, Dr. Williams was at Pfizer in the UK and the USA as a clinical triallist in Translational Medicine, and subsequently as VP, Global Clinical Technology. He sat on the National Advisory Council for the National Institute of Biomedical Imaging and Bioengineering, the Executive Committee for the FNIH Biomarkers Consortium, and worked with FDA and PhRMA on developing evidentiary standards for biomarker qualification. Dr. William’s medical training was in London, at Charing Cross and Westminster Medical School, followed by a PhD in medicine/physiology at the same institution and training in Radiology at the University of Newcastle Upon Tyne. Steve is co-inventor on 26 proteomics patents and author/coauthor on multiple foundational proteomics manuscripts.

Justin McAnear

CFO

Mr. McAnear serves as the company’s Chief Financial Officer. He brings over 25 years of operational and financial leadership experience across various sectors and was instrumental in taking 10x Genomics public in 2019, serving as its CFO for over five years. Mr. McAnear served for over 3 years as Tesla’s VP of Worldwide Finance and Operations, supporting landmark initiatives such as the Model X and Model 3 launches and Solar City acquisition.  He also held various roles at Apple and J&J earlier in his career and served as a naval officer and aviator for over 9 years.